1048 related articles for article (PubMed ID: 16528530)
21. 5-Fluorouracil enhances azidothymidine cytotoxicity: in vitro, in vivo, and biochemical studies.
Brunetti I; Falcone A; Calabresi P; Goulette FA; Darnowski JW
Cancer Res; 1990 Jul; 50(13):4026-31. PubMed ID: 2354452
[TBL] [Abstract][Full Text] [Related]
22. Modulation of plasma uridine concentration by 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase: relevance to chemotherapy.
Ashour OM; Al Safarjalani ON; Naguib FN; Goudgaon NM; Schinazi RF; el Kouni MH
Cancer Chemother Pharmacol; 2000; 45(5):351-61. PubMed ID: 10803917
[TBL] [Abstract][Full Text] [Related]
23. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
[TBL] [Abstract][Full Text] [Related]
24. Enhanced cytotoxicity with interleukin-1 alpha and 5-fluorouracil in HCT116 colon cancer cells.
Geoffroy FJ; Allegra CJ; Sinha B; Grem JL
Oncol Res; 1994; 6(12):581-91. PubMed ID: 7787251
[TBL] [Abstract][Full Text] [Related]
25. Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo.
Kase S; Kubota T; Watanabe M; Furukawa T; Tanino H; Ishibiki K; Teramoto T; Kitajima M
Anticancer Res; 1993; 13(2):369-73. PubMed ID: 8517649
[TBL] [Abstract][Full Text] [Related]
26. Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
Sakurai Y; Yoshida I; Kamoshida S; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
Ann Surg Oncol; 2008 Aug; 15(8):2301-9. PubMed ID: 18506536
[TBL] [Abstract][Full Text] [Related]
27. Anti-tumor efficacy of Cloretazine (VNP40101M) alone and in combination with fludarabine in murine tumor and human xenograft tumor models.
Zheng LM; Li Z; Liu L; Song BL; King I
Cancer Chemother Pharmacol; 2007 Jun; 60(1):45-51. PubMed ID: 17256135
[TBL] [Abstract][Full Text] [Related]
28. 5-Fluorouracil treatment of a human colon adenocarcinoma implanted in the subrenal capsule site of athymic mice.
Zimmerman RJ; VanWinkle TJ; Mantel N; Frei E; Goldin A
Cancer Res; 1986 Feb; 46(2):694-700. PubMed ID: 3940636
[TBL] [Abstract][Full Text] [Related]
29. Clinical studies of biochemical modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer by the North Central Cancer Treatment Group and Mayo Clinic.
O'Connell MJ; Klaassen DJ; Everson LK; Cullinan S; Wieand HS
NCI Monogr; 1987; (5):185-8. PubMed ID: 3501540
[TBL] [Abstract][Full Text] [Related]
30. In vitro synergism between 5-fluorouracil and natural beta interferon in human colon carcinoma cells.
Guglielmi A; Aschele C; Mori A; Baldo C; Russo P; Debernardis D; Valenti M; Bruno S; Taverna M; Rosso R
Clin Cancer Res; 1995 Nov; 1(11):1337-44. PubMed ID: 9815929
[TBL] [Abstract][Full Text] [Related]
31. Modulation of chemotherapeutic drug activity with polyribonucleotides or with interferon.
Stolfi RL; Martin DS
J Biol Response Mod; 1985 Dec; 4(6):634-9. PubMed ID: 2418161
[TBL] [Abstract][Full Text] [Related]
32. In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor.
Uckun FM; Narla RK; Zeren T; Yanishevski Y; Myers DE; Waurzyniak B; Ek O; Schneider E; Messinger Y; Chelstrom LM; Gunther R; Evans W
Clin Cancer Res; 1998 May; 4(5):1125-34. PubMed ID: 9607569
[TBL] [Abstract][Full Text] [Related]
33. Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer.
Cao S; Troutt AB; Rustum YM
Cancer Res; 1998 Apr; 58(8):1695-9. PubMed ID: 9563485
[TBL] [Abstract][Full Text] [Related]
34. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.
Munoz R; Man S; Shaked Y; Lee CR; Wong J; Francia G; Kerbel RS
Cancer Res; 2006 Apr; 66(7):3386-91. PubMed ID: 16585158
[TBL] [Abstract][Full Text] [Related]
35. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
[TBL] [Abstract][Full Text] [Related]
36. Antitumor efficacy of edotecarin as a single agent and in combination with chemotherapy agents in a xenograft model.
Ciomei M; Croci V; Ciavolella A; Ballinari D; Pesenti E
Clin Cancer Res; 2006 May; 12(9):2856-61. PubMed ID: 16675581
[TBL] [Abstract][Full Text] [Related]
37. Anti-tumour effects of triple therapy with octreotide, galanin and serotonin in comparison with those of 5-fluorouracil/leukovorin on human colon cancer.
Tjomsland V; El-Salhy M
Int J Oncol; 2005 Aug; 27(2):427-32. PubMed ID: 16010424
[TBL] [Abstract][Full Text] [Related]
38. Enhanced antitumor activity of 5-fluorouracil in combination with 2'-deoxyinosine in human colorectal cell lines and human colon tumor xenografts.
Ciccolini J; Peillard L; Evrard A; Cuq P; Aubert C; Pelegrin A; Formento P; Milano G; Catalin J
Clin Cancer Res; 2000 Apr; 6(4):1529-35. PubMed ID: 10778986
[TBL] [Abstract][Full Text] [Related]
39. [Effect and mechanism of orally administered leucovorin/5-fluorouracil on colon cancer].
Iba T; Kidokoro A; Fukunaga M; Sugiyama K; Fukunaga T; Aihara N
Gan To Kagaku Ryoho; 2003 Dec; 30(13):2077-81. PubMed ID: 14712768
[TBL] [Abstract][Full Text] [Related]
40. Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine.
Martin DS; Stolfi RL; Sawyer RC
Cancer Chemother Pharmacol; 1989; 24(1):9-14. PubMed ID: 2720896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
